Broad capabilities, established expertise


As one of the world’s most renowned companies for contract development and manufacturing, we are recognized for our reliable, high-quality service, our global capacity, our innovative technology platforms, and our extensive experience. In 2019 we provided manufacturing services for more than 300 commercial molecules and supported the development of more than 700 pre-clinical and clinical molecules in small and large molecules as well as supporting the launch of pioneering autologous cell therapies.

 

Success for us is when you, as our partner, are fully satisfied. We continuously improve and innovate to meet your expectations and improve your chances of business success. Our broad capabilities span across biologics, small molecules, bioconjugates, and cell and gene therapies. We manage projects from pre-clinical stage through to commercialization, and our expertise covers both drug substance and drug product.

Trending now

Streamlined Selection of In Vivo Predictive Dissolution Media
Our expert in enabling bioavailability-enhancing amorphous solid dispersions - Deanna Mudie, Ph.D., Principal Scientist in Research and Development - will present a webinar titled, “Streamlined selection of in vivo predictive dissolution media” on Wednesday, September 29 at 11am EDT/ 5pm CEST.
Lonza & Me
Learn about the journeys of small biotechs that are working with Lonza. Owners and others tell their stories about their initial idea, what led them to Lonza, and their experiences with us.
Lonza and Sheba Medical Center Use Cocoon® Platform and Show Successful Clinical Outcomes in Patients Treated with CAR-T Cell Immunotherapy
Four patients have been successfully dosed at Sheba Medical Center, Israel, with a CD19 autologous CAR-T cell therapy using Lonza’s Cocoon® automated manufacturing Platform
We believe that the best outcome – for you and for your patients – can only come as a result of a successful collaboration. Together, we can solve the next challenge and bring your next medicine to life.

In the news


We have a broad view on the industry, and a depth of experience in developing and manufacturing therapies. Our scientific teams focus on devising credible, game-changing solutions that create value for our customers today by delivering the medicines of tomorrow.

View press releases

Our global footprint


With 37 sites across three continents and 11,148 employees, we capitalize on our global footprint and have the flexibility to address regional and even local marketplace needs.

View our locations